Cargando…

Repurposing cabozantinib with therapeutic potential in KIT-driven t(8;21) acute myeloid leukaemias

Cabozantinib is an orally available, multi-target tyrosine kinase inhibitor approved for the treatment of several solid tumours and known to inhibit KIT tyrosine kinase. In acute myeloid leukaemia (AML), aberrant KIT tyrosine kinase often coexists with t(8;21) to drive leukaemogenesis. Here we evalu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Kuan-Wei, Ou, Da-Liang, Fu, Yu-Hsuan, Tien, Hwei-Fang, Hou, Hsin-An, Lin, Liang-In
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113930/ https://www.ncbi.nlm.nih.gov/pubmed/33833412 http://dx.doi.org/10.1038/s41417-021-00329-1

Ejemplares similares

ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation
por: Hartmann, Luise, et al.
Publicado: (2016)

Modelling t(8;21) acute myeloid leukaemia ‐ What have we learned?
por: Chin, Paulynn Suyin, et al.
Publicado: (2020)

Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21)
por: Qin, Ya-Zhen, et al.
Publicado: (2018)

The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia
por: Qin, Ya-Zhen, et al.
Publicado: (2021)

Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia
por: Issa, Hasan, et al.
Publicado: (2023)

PB1814: THERAPEUTIC POTENTIAL AND STRATEGIES OF PIM447, A PAN-PIM INHIBITOR, TARGETING REFRACTORY MYELOID LEUKEMIA WITH KIT-DRIVEN T(8/21)
por: Tseng, Chi-Yang, et al.
Publicado: (2023)

Acute Myeloid Leukaemia With Translocation (8;21) Masquerading as Peripheral Blood Eosinophilia Having Dysplastic Features: A Diagnostic Challenge
por: Singh, Anurag, et al.
Publicado: (2023)

High Expression of c-kit mRNA Predicts Unfavorable Outcome in Adult Patients with t(8;21) Acute Myeloid Leukemia
por: Gao, Xiaoning, et al.
Publicado: (2015)

Single-cell RNA sequencing of t(8;21) acute myeloid leukemia for risk prediction
por: Xiong, Qian, et al.
Publicado: (2020)

Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications
por: Reikvam, Håkon, et al.
Publicado: (2011)

Translocation (8;21) acute myeloid leukemia presenting as severe aplastic anemia
por: Purev, Enkhtsetseg, et al.
Publicado: (2014)

P437: EFFECTIVE IMMUNOTHERAPY OF PEDIATRIC T(8;21) ACUTE MYELOID LEUKEMIA BY REPURPOSING CD3XCD19 TARGETING BISPECIFIC ANTIBODIES
por: Wijnen, Noa, et al.
Publicado: (2023)

Epigenetic silencing of UBXN8 contributes to leukemogenesis in t(8;21) acute myeloid leukemia
por: Yang, Erna, et al.
Publicado: (2021)

Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial
por: Ruhnke, Leo, et al.
Publicado: (2023)

A Novel KIT INDEL Mutation in Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1
por: Lee, Jun Hyung, et al.
Publicado: (2016)

Role of CD19 and specific KIT‐D816 on risk stratification refinement in t(8;21) acute myeloid leukemia induced with different cytarabine intensities
por: Wang, Biao, et al.
Publicado: (2020)

Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
por: Li, Zheng, et al.
Publicado: (2022)

Targeting miR‐193a‐AML1‐ETO‐β‐catenin axis by melatonin suppresses the self‐renewal of leukaemia stem cells in leukaemia with t (8;21) translocation
por: Zhou, Bin, et al.
Publicado: (2019)

Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia
por: Pullarkat, Sheeja T., et al.
Publicado: (2009)

A case of acute myeloid leukemia-M2 with trisomy 4 in addition to t(8;21)
por: Trivedi, P. J., et al.
Publicado: (2008)

Methylation-associated silencing of BASP1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia
por: Zhou, Lei, et al.
Publicado: (2018)

Celastrol Induces Cell Apoptosis and Inhibits the Expression of the AML1-ETO/C-KIT Oncoprotein in t(8;21) Leukemia
por: Yu, Xianjun, et al.
Publicado: (2016)

A new inducible model for t(8;21) AML
por: Mulloy, James C
Publicado: (2013)

Isolated Pancreatic Myeloid Sarcoma Associated with t(8;21)/RUNX1-RUNX1T1 Rearrangement
por: Tokunaga, Kenji, et al.
Publicado: (2017)

Glucocorticoids Inhibit Oncogenic RUNX1-ETO in Acute Myeloid Leukemia with Chromosome Translocation t(8;21)
por: Lu, Lianghao, et al.
Publicado: (2018)

High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia
por: Yang, Lu, et al.
Publicado: (2019)

Clinical, Cytogenetic, and Molecular Findings in Two Cases of Variant t(8;21) Acute Myeloid Leukemia (AML)
por: Wilde, Lindsay, et al.
Publicado: (2019)

KIT D816突变对伴t(8;21)复发急性髓系白血病预后的影响
Publicado: (2018)

t(8;21) Acute Myeloid Leukemia as a Paradigm for the Understanding of Leukemogenesis at the Level of Gene Regulation and Chromatin Programming
por: Kellaway, Sophie, et al.
Publicado: (2020)

JAK inhibitors suppress t(8;21) fusion protein-induced leukemia
por: Lo, Miao-Chia, et al.
Publicado: (2013)

我如何治疗t（8；21）急性髓系白血病
Publicado: (2017)

Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1)
por: Meyer, Tatjana, et al.
Publicado: (2019)

Successful Outcome of a Case of Acute Myeloid Leukemia with t(8;21)/AML-ETO Following Langerhans Cell Histiocytosis
por: Meng, Guangqiang, et al.
Publicado: (2019)

Low IL7R Expression at Diagnosis Predicted Relapse in Adult Acute Myeloid Leukemia Patients With t(8;21)
por: Xu, Nan, et al.
Publicado: (2022)

Chidamide inhibits t(8;21) AML cell proliferation and AMK1/ETO and C-KIT expression by inhibiting ERK1/2 signaling pathway
por: Liu, Jing, et al.
Publicado: (2020)

POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature
por: Fortier, Julie M., et al.
Publicado: (2010)

Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit)
por: Ustun, Celalettin, et al.
Publicado: (2018)

PB1815: ADDITIONAL СYTOGENETIC ABNORMALITIES IN ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)
por: Zotova, Olena, et al.
Publicado: (2023)

Has Drug Repurposing Fulfilled Its Promise in Acute Myeloid Leukaemia?
por: Valli, Debora, et al.
Publicado: (2020)

Cytarabine-Resistant FLT3-ITD Leukemia Cells are Associated with TP53 Mutation and Multiple Pathway Alterations—Possible Therapeutic Efficacy of Cabozantinib
por: Ko, Ya-Chen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2a44vl5tugvrbn760eaiho3fl1